Weight Management

Question 1

What are incretin receptor agonists?

Accepted Answer

Incretin receptor agonists are peptides that mimic the action of endogenous gut hormones such as GLP-1 (Glucagon-like Peptide 1) and GIP (Glucose-dependent Insulinotropic Polypeptide). In metabolic research they serve as tools to probe the mechanisms of insulin secretion, gastric emptying, satiety signaling, and energy balance. By selectively activating one or several incretin receptors, investigators can dissect their individual contributions to glucose regulation and fat metabolism. Triple agonists such as Retatrutide add a Glucagon receptor arm, allowing researchers to study combined effects on appetite, insulin response, and energy expenditure within a single molecule.

Question 2

How do mono, dual and triple agonists differ?

Accepted Answer

The difference lies in the number of receptors engaged at once. A mono agonist such as Semaglutide binds only the GLP-1 receptor and serves in this category as a comparison molecule (not a Bergdorf product). Tirzepatide is a dual agonist at GLP-1 and GIP; the additional GIP arm is linked in studies to effects on insulin secretion and lipid metabolism. Retatrutide is a triple agonist at GLP-1, GIP, and Glucagon (GCG); the glucagon arm is associated with increased energy expenditure and hepatic fat metabolism. With each additional receptor arm, the set of metabolic endpoints researchers can compare in preclinical models grows. Tirzepatide has a half-life of roughly 5 days and Retatrutide roughly 6 days, which supports weekly dosing intervals in study designs for both.

Question 3

What is GLP-1 studied for?

Accepted Answer

GLP-1 is an endogenous incretin hormone released from intestinal L-cells after nutrient intake and amplifies insulin secretion in a glucose-dependent manner. In research, GLP-1 receptor agonists are used to study the mechanisms of blood-glucose regulation, gastric emptying, central satiety perception, and hepatic gluconeogenesis. They also act as reference ligands in receptor-binding and signaling pathway assays. Multi-agonists such as Retatrutide and Tirzepatide extend this toolset with additional receptor arms and let investigators compare how combining several incretin pathways shifts metabolic endpoints in preclinical models, including body weight, adiposity, and glucose tolerance.

Question 4

How do Tirzepatide and Retatrutide differ mechanistically?

Accepted Answer

Both are multi-incretin agonists but differ in the number of receptors they engage. Tirzepatide is a dual agonist at GLP-1 and GIP: the GLP-1 arm covers glucose-dependent insulin secretion and satiety, while the GIP arm is additionally linked in studies to insulin secretion and lipid metabolism. Retatrutide adds the Glucagon receptor (GCG) as a triple agonist; this third arm is associated with increased energy expenditure and hepatic fat metabolism. In preclinical models, the additional glucagon arm allows researchers to probe mechanisms that go beyond the incretin signal alone. The half-lives are roughly 5 days (Tirzepatide) and roughly 6 days (Retatrutide), which supports weekly intervals in study designs.

Question 5

What role do MOTS-c and NAD+ play in this category?

Accepted Answer

MOTS-c and NAD+ represent the non-incretin, metabolic side of the category. MOTS-c is a mitochondrially encoded peptide linked in research to the AMPK pathway and cellular energy balance (Lee et al., Cell Metabolism 2015); its half-life is roughly 12 hours, so it is typically studied in shorter-interval designs. NAD+ is a redox cofactor used in studies of energy metabolism and longevity as a systemic substrate; its plasma half-life sits in the range of roughly 1 to 2 hours. Both address metabolism through mechanisms distinct from the incretins and are used in research as complementary tools to study mitochondrial and appetite-driven pathways side by side.

Question 6

What do AOD-9604 and HGH Fragment 176-191 model?

Accepted Answer

AOD-9604 and HGH Fragment 176-191 reproduce the C-terminal, lipolytically active segment of human growth hormone; AOD-9604 is a stabilized variant carrying an additional tyrosine residue at the N-terminus. In preclinical models they are used to study lipolysis and fat oxidation directly in the adipocyte, and without relevant elevation of IGF-1 levels. This allows the fat-metabolism-related effects to be characterized in isolation from the anabolic, IGF-1-mediated axis of growth hormone. Within this category they serve as a lipolytic comparison arm to the incretin agonists, whose action is mediated primarily through appetite and glucose signaling pathways. Their half-lives are short, roughly 2.5 hours for HGH Fragment 176-191 and roughly 3 hours for AOD-9604.

Question 7

What does Research Use Only (RUO) mean?

Accepted Answer

Research Use Only (RUO) designates reagents and substances intended solely for laboratory research in vitro and for preclinical models. They are not approved as medicines and must not be used therapeutically in humans or animals. RUO is an internationally established label that draws clear lines of responsibility and lets research institutions source qualified active ingredients in a compliant way. Every peptide in this category is distributed exclusively under RUO status. Use and interpretation are the responsibility of the researcher and their institution, including all relevant safety, ethics, and approval procedures that apply to their study.

Question 8

How are the peptides reconstituted?

Accepted Answer

For experimental work they are typically reconstituted with bacteriostatic water. The diluent should be added slowly down the wall of the vial and the solution then mixed by gentle rotation rather than shaking; peptides are sensitive to shear forces, and vigorous shaking promotes foaming and degradation. The calculated volume follows the target concentration, vial size, and study protocol; the sequence and molecular-weight data on the product page allow weighing and working concentration to be computed precisely. The finished solution should be aliquoted promptly to avoid repeated freeze-thaw cycles. Detailed guidance on target concentrations and volumes is available in the research guides for Retatrutide and Tirzepatide.

Question 9

How are the peptides stored?

Accepted Answer

In lyophilized form the peptides are stable at minus 20 °C for 24 months. Vials should be kept dry, protected from light, and unopened until use. After reconstitution with bacteriostatic water, the solution is usable at 2 to 8 °C for 28 days. Repeated freeze-thaw cycles should be avoided; aliquoting into smaller portions limits quality loss from mechanical and thermal stress and keeps the solution fit for quantitative assays. Protection from light during storage and handling additionally preserves peptide integrity, which matters in particular for the long half-life incretin agonists where reproducible results depend on stable stock.

Question 10

What documentation and CoA do I receive?

Accepted Answer

For every peptide a Certificate of Analysis (CoA) is available on request, documenting HPLC purity of 99% and mass-spectrometric identity confirmation for the respective batch. The CoA is mapped unambiguously to the specific peptide. In addition, each product page lists the molecular weight, amino acid sequence, and, where published, the receptor affinity, so that weighing and dilution series can be computed against your own experimental protocol without further inquiry. The entire category is labeled Research Use Only; the documentation evidences purity and identity but does not replace a pharmaceutical quality regime and applies exclusively to the research context.

Question 11

How do the half-lives differ across this category?

Accepted Answer

Half-lives range from hours to several days and shape the study design substantially. The incretin agonists are long-acting: Tirzepatide is roughly 5 days and Retatrutide roughly 6 days, which supports weekly intervals in preclinical protocols. The metabolic and mitochondrial tools are considerably shorter: MOTS-c is roughly 12 hours, HGH Fragment 176-191 roughly 2.5 to 3 hours, and NAD+ as a cofactor only about 1 to 2 hours. This spread means short half-life substances are studied within tighter time windows, while the incretin agonists map accumulation and steady-state across several days. Detailed half-life profiles are available in the respective research guides.

Peptide	Mechanism	Half-life	Purity	From
Retatrutide	GLP-1 / GIP / GCG	~6 days	≥99.2%	$119.99	View →
Tirazeptid 60mg	GLP-1 / GIP	~5 days	≥99.0%	$49.99	View →

Peptide	Mechanism	Half-life	Purity	From
Retatrutide	GLP-1 / GIP / GCG	~6 days	≥99.2%	$119.99	View →
Tirazeptid 60mg	GLP-1 / GIP	~5 days	≥99.0%	$49.99	View →

Weight Management

Retatrutide

Tirazeptid 60mg

Combine an incretin and metabolic stack

Peptides in Weight Management compared

Questions about Weight Management